"The cystic fibrosis (CF) drug Orkambi (Vertex Pharmaceuticals) has received a green light from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).
Orkambi is a fixed-dose oral combination "...
(Generic versions may still be available.)
Electrocardiographic monitoring should be instituted and the patient carefully observed for the possible development of arrhythmias; if required, appropriate antiarrhythmic therapy should be given. Consideration should be given to the possibility of multiple drug ingestion by the patient. To date, no experience has been reported with dialysis; hence its value in Larodopa overdosage is not known. Although pyridoxine hydrochloride (vitamin B6) has been reported to reverse the anti-Parkinson effects of Larodopa, its usefulness in the management of acute overdosage has not been established.
Monoamine oxidase (MAO) inhibitors and Larodopa should not be given concomitantly and these inhibitors must be discontinued 2 weeks prior to initiating therapy with Larodopa. Larodopa is contraindicated in patients with known hypersensitivity to the drug and in narrow angle glaucoma.
Last reviewed on RxList: 12/8/2004
Additional Dopar Information
- Dopar Drug Interactions Center: levodopa oral
- Dopar Side Effects Center
- Dopar FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.